Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Genmab ( (GMAB) ) is now available.
On March 4, 2026, Genmab A/S filed a Form 6-K in the United States, updating investors with its revised Articles of Association, which formally set out the company’s corporate structure and capital framework. The filing confirms a registered share capital of DKK 64,250,721 and designates English as the group language, underscoring Genmab’s international orientation.
The updated Articles provide the board of directors with broad authorizations, valid mainly until March 12, 2029, to increase share capital with or without pre-emptive rights, issue employee warrants and convertible debt, and adjust the Articles accordingly. These measures, which stem from shareholder decisions between 2021 and 2025, give Genmab significant flexibility to fund growth, incentivize staff and manage its capital structure, potentially affecting future dilution and governance for existing shareholders.
The most recent analyst rating on (GMAB) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.
The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is a Danish biotechnology company based in Copenhagen, focused on medical research, production and sale of pharmaceutical products. The company operates in the biopharmaceutical and oncology space, developing antibody-based therapies and related technologies for global markets.
Average Trading Volume: 1,731,777
Technical Sentiment Signal: Buy
Current Market Cap: $16.95B
See more data about GMAB stock on TipRanks’ Stock Analysis page.